Toxicology and overdose of atypical antipsychotic medications in children: Does newer necessarily mean safer?

Current Opinion in Pediatrics

Volumn 17, Issue 2, 2005, Pages 227-233

  DuBois, Dale ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical antipsychotic; Overdose; Therapeutic monitoring; Toxicology

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CLOZAPINE; DANTROLENE; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; OLANZAPINE; OMEPRAZOLE; OPIATE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PINDOLOL; PROPRANOLOL; PROPRANOLOL DERIVATIVE; QUETIAPINE; QUINIDINE; RIFAMPICIN; RISPERIDONE; UNINDEXED DRUG; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; ANHIDROSIS; CARDIOMYOPATHY; CHILD; CONSTIPATION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISORIENTATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTHERMIA; HYPOTENSION; INCONTINENCE; LEARNING DISORDER; LEUKOCYTOSIS; LEUKOPENIA; LIVER TOXICITY; MEMORY DISORDER; MUTISM; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; PANCREATITIS; PARKINSONISM; PEDIATRIC SURGERY; PHARMACODYNAMICS; PRESCRIPTION; PRIAPISM; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; REVIEW; RISK REDUCTION; SEDATION; SEIZURE; SIDE EFFECT; TACHYCARDIA; TREMOR; UNITED STATES; URINE RETENTION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; CARDIOMYOPATHIES; CHILD; CLOZAPINE; DIABETES MELLITUS; DIBENZOTHIAZEPINES; DRUG INTERACTIONS; DRY EYE SYNDROMES; HUMANS; HYPERLIPIDEMIAS; HYPOTENSION; OVERDOSE; PIPERAZINES; QUINOLONES; RISPERIDONE; SEIZURES; THIAZOLES;

EID: 17144413815     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000151714.87702.a9     Document Type: Review

References (54)

1. Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 2004; 65(suppl 6):30-44.
2. Del Bello M, Grcevich S. Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical antipsychotics. J Clin Psychiatry 2004; 65(suppl 6):12-19.
3. Freedman R, Schizophrenia. N Engl J Med 2003; 349:1738-1749. A good review of the pathophysiology of schizophrenia and its treatments.
4. Trenton AJ, Currier GW, Zwemer FL. Fatalities associated with therapeutic use and overuse of atypical antipsychotics. CNS Drugs 2003; 17:307-324. A review of serious side effects of atypical antipsychotics.
5. Watson WA, Litovitz TL, Klein-Schwartz W, et al. 2003 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Available at: http://www.aapcc.org. Accessed October 24, 2004. A report including atypical antipsychotic overdoses and fatalities in the United States in 2003.
6. Important Correction of Drug Information: Letter, Janssen Pharmaceutica, Inc. July 21, 2004. An example of how we may be underestimating the adverse effects of atypical antipsychotics.
7. Burns MJ. The pharmacology and toxicity of atypical antipsychotic agents. Clin Toxicol 2001; 39:1-14.
8. Tamminga CA. Similarities and differences among antipsychotics. J Clin Psychiatry 2003; 64(suppl 17):7-10. A look at the differing pharmacodynamics of the atypical antipsychotics.
9. Clozapine prescribing information. Mylan Pharmaceuticals, Inc. April, 2002.
10. Risperidone prescribing information. Janssen Pharmaceutica Products. April, 2003.
11. Olanapine prescribing information. Eli Lilly and Co. January, 2003.
12. Quetiapine prescribing information. AstraZeneca Pharmaceutical. March, 2003.
13. Ziprasidone prescribing information. Pfizer, Inc. December, 2003.
14. Aripiprazole prescribing information. Bristol-Myers Squibb Company. May, 2003.
15. Levine M, Traub S, Burns MJ. The pharmacology and toxicology of aripiprazole. Int J Med Toxicol 2004; 7:5. A comprehensive review of the newest atypical antipsychotic.
16. MICROMEDEX® Healthcare Series, Thompson MICROMEDEX Greenwood Village, Colorado. Vol 122.
17. th ed. Edited by Hardman JG, Limbird LE, Goodman-Gilman A. New York: McGraw-Hill; 2001:485-520.
18. McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychol 2004; 65(suppl 6):20-29.
19. Davis JM, Chen N. Dose response and done equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24:192-203. Recommendations of the maximum doses of atypical antipsychotics where there is little further clinical benefit and side effect risks are increased.
20. Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q 2002; 73:297-311.
21. Jacobs ES, Dickstein DP, Liebelt EL. Novel psychotropic medications in children: new toxicities to master. Pediatr Emerg Care 2001; 17:226-231.
22. Duggal HS, Gates C, Pathak PC. Olanzapine induced neutropenia: mechanism and treatment. J Clin Psychopharmacol 2004; 24:234-233.
23. Centorrino F, Price BH, Tuttle M. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry 2002; 151:109-115.
24. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004; 65(suppl 9): 25-28. A review of proposed mechanisms of drug-induced EPS.
25. Schillevoort I, de Boer A, Herings R, et al. The risk of extrapyamidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother 2001; 35:1517-1522.
26. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414-425. A review of 11 studies lasting 1 year showing lower risk of TD with atypical antipsychotics compared to first-generation antipsychotics.
27. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004; 65(suppl 9):16-20. A review of studies showing prevalence and incidence of TD with atypical antipsychotics.
28. Velamoor VR. Neuroleptic malignant syndrome. Drug Saf 1998; 19:73-82.
29. Ananth JA, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65:464-470. A review of case reports of NMS with atypical antipsychotics including fatalities.
30. Kang UG, Kwon JS, Ahn YM, et al. Electrocardiograpic abnormalities in patients treated with clozapine. J Clin Psychiatry 2000; 61:441-446.
31. Czekalla J, Kollack-Walker S, Beasley CM. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry 2001; 62(suppl 2):35-40.
32. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, Torsade de Pointes, and sudden death. Drugs 2002; 62:1649-1671.
33. Harrigan EP, Miceli JJ, Watsky E, et al. A Randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24:62-69. A prospective, randomized study investigating the effects of first-generation and atypical antipsychotics on the QTc interval during the time of peak exposure (aripiprazole was not included).
34. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics. Drugs 2004; 64:701-723.
35. Casey DE, Haupt DW, Newcomer JW. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65(suppl 7):4-18. A review of metabolic complications associated with atypical antipsychotics.
36. Baptista T. Mechanisms of weight gain induced by antipsychotic drugs. J Clin Psychiatry 2002; 63:245-246.
37. Jones BJ, Basson BR, Walker DJ, et al. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001; 62(suppl 2):41-44.
38. Menza M, Vreeland B, Minsky S, et al. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004; 65:471-477. A study showing that weight control programs focusing on nutrition, exercise, and motivation can minimize weight gain in patients treated with atypical antipsychotics.
39. Lamberti JS, Crilly JF, Maharaj K, et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 2004; 65:702-706.
40. Spoelstra JA, Stolk RP, Cohen D, et al. Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. J Clin Psychiatry 2004; 65:674-678. A cohort study showing increased risk for need of insulin therapy in type 2 diabetics on antipsychotic medications.
41. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63:856-865.
42. Howes O, Bhatnagar A, Gaughran FP, et al. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 2004; 161:361-363. A study proposing an impaired glucose control with atypical antipsychotic use is unrelated to insulin sensitivity.
43. Ragucci KR, Wells B. Olanzapine-induced diabetic ketoacidosis. Ann Pharmacother 2001; 35:1556-1558.
44. Saari K, Koponen H, Laitinen J, et al. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry 2004; 65:547-550. A study indicating an elevated risk of hyperlipidemia in persons using antipsychotic medications independent of other risk factors.
45. Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004; 65:57-61. A double-blind, randomized study showing hyperprolactinemia with risperidone and not with other atypical antipsychotics studied.
46. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334-1349. Recommendations of therapeutic monitoring of patients on atypical antipsychotic treatment.
47. McIntyre JS, Charles SC, Altshuler K, et al. Treatment recommendations for patients with schizophrenia. Am J Psychiatry 2004; 161(2 suppl):3-56. A comprehensive literature review and development of practice guidelines for treatment of patients with schizophrenia.
48. Capel MM, Colbridge MG, Henry JA. Overdose profiles of new antipsychotic agents. Int J Neuropsychopharmacol 2000; 3:51-54.
49. Palenzona S, Meier PJ, Kupferschmidt H, Rauber-Luethy C. The clinical picture of olanzapine poisoning with special reference to fluctuating mental status. J Toxicol Clin Toxicol 2004; 42:27-32. A review of 26 cases of olanzapine monoingestions describing the clinical picture with olanzapine overdose.
50. Balit CR, Isbister GK, Hackett LP, Whyte IM. Quetiapine poisoning: a case series. Ann Med 2003; 42:751-758. A review of 18 cases of quetiapine overdosages (six being monoingestions) describing the clinical profiles of these cases.
51. Acri AA, Henretig FM. Effects of risperidone in overdose. Am J Med 1998; 16:498-501.
52. Catalano G, Catalane MC, Nunez CY, Walker SC. Atypical antipsychotic overdose in the pediatric population. J Child Adolesc Psychopharmacol 2001; 11:425-434.
53. Burton S, Heslop K, Harrison K, Barnes M. Ziprasidone overdose. Am J Psychiatry 2000; 157:835.
54. House M. Overdose of ziprasidone. Am J Psychiatry 2002; 159:1061.